| Literature DB >> 24843573 |
Yasuyuki Jin1, Akira Kanamori1, Shogo Ito1, Kiyokazu Matoba1, Masaaki Miyakawa1, Hideaki Kaneshige1, Mitsuo Obana1, Masahiko Takai1, Hiroshi Takeda1, Hideo Machimura1, Nobuaki Minami1, Takahiro Kawata1, Shin Honda1, Sachio Aoyagi1, Hikaru Amemiya1, Nobuo Sasai1, Michio Nakayama1, Yoshikazu Naka1, Yasuo Terauchi2, Ikuro Matsuba1.
Abstract
UNLABELLED: Aims/Introduction: The prevalence of diabetes mellitus is increasing rapidly in Japan, and diabetic neuropathy is a major factor decreasing diabetic patients' quality of life, as well as a risk factor for sudden death. The present study aimed to determine the prevalence of diabetic neuropathy and raise awareness about it among patients and their physicians.Entities:
Keywords: Diabetic neuropathies; Diagnosis; Epidemiology
Year: 2012 PMID: 24843573 PMCID: PMC4014946 DOI: 10.1111/j.2040-1124.2011.00174.x
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Patient profiles.
|
| (%) | |
|---|---|---|
| Total | 5077 | |
| Type of diabetes | ||
| Type 1 | 145 | (2.9) |
| Type 2 | 4182 | (82.4) |
| Unknown | 750 | (14.8) |
| Sex | ||
| Male | 2721 | (53.6) |
| Female | 2302 | (45.3) |
| Unknown | 54 | (1.1) |
| Age (years) | ||
| 64 ± 12 | ||
| Unknown | 54 | (1.1) |
| Duration of diabetes (years) | ||
| 10 ± 8 | ||
| Unknown | 504 | (9.9) |
| BMI (kg/m2) | ||
| 24.2 ± 3.9 | ||
| ≥25 | 1842 | (36.3) |
| <25 | 3149 | (62.0) |
| Unknown | 86 | (1.7) |
| HbA1c (%, NGSP) | ||
| 7.8 ± 1.5 | ||
| Unknown | 142 | (2.8) |
| Treatment of diabetes | ||
| Diet and exercise therapy | 915 | (18.0) |
| Oral Hypoglycemic agent | 3300 | (65.0) |
| Insulin | 862 | (17.0) |
| Medication for neuropathy | ||
| + | 852 | (16.8) |
| − | 4225 | (83.2) |
| Epalrestat | 445 | (8.8) |
| Mecobalamin | 391 | (7.7) |
| Mexiletine hydrochloride | 80 | (1.6) |
| Goshajinki‐gan | 35 | (0.7) |
| NSAIDS | 33 | (0.6) |
| Others | 76 | (1.5) |
Data (age, duration of diabetes, BMI, HbA1c) are expressed as mean ± SD.
Frequency of subjective symptoms and abnormal findings on neurological examinations
| Subjective symptoms of the feet | Mild | Moderate | Severe | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Symptom of sensory nervous system | ||||||||
| Numbness/Tingling | 935 (18.4) | 327 (6.4) | 69 (1.4) | 1331 (26.2) | ||||
| Pain | 308 (6.1) | 88 (1.7) | 18 (0.4) | 414 (8.2) | ||||
| Cold | 1202 (23.7) | 413 (8.1) | 103 (2.0) | 1718 (33.8) | ||||
| Hypoesthesia | 637 (12.5) | 206 (4.1) | 59 (1.2) | 902 (17.8) | ||||
| Paresthesia | 318 (6.3) | 110 (2.2) | 37 (0.7) | 465 (9.2) | ||||
| Dysesthesia | 309 (6.1) | 80 (1.6) | 18 (0.4) | 407 (8.0) | ||||
| Symptom of motor nervous system | ||||||||
| Muscle cramps | 1652 (32.5) | 346 (6.8) | 68 (1.3) | 2066 (40.7) | ||||
| Symptom of autonomic nervous system | ||||||||
| Dizziness and orthostatic hypotension | 1190 (23.4) | 177 (3.5) | 33 (0.6) | 1400 (27.6) | ||||
| Gastrointestinal symptoms | 1206 (23.8) | 332 (6.5) | 82 (1.6) | 1620 (31.9) | ||||
| Sudomotor dysfunction | 735 (14.5) | 255 (5.0) | 66 (1.3) | 1056 (20.8) | ||||
| Vibration perception of medial malleolus | Normal | Abnormal (< 10 s) | ||||||
|
| 1134 | (29.6) | 2692 | (70.4) | ||||
| Achilles tendon reflex | Normal | Abnormal unilateral | Abnormal bilateral | |||||
|
| 2408 | (48.2) | 346 | (6.9) | 2247 | (44.9) | ||
| Light touch sensation of the great toe | Normal | Diminished | Loss | |||||
|
| 3294 | (68.6) | 939 | (19.5) | 572 | (11.9) | ||
Data are numbers of patients and percentage in parentheses.
Patient profiles of the two groups
| Diabetic neuropathy |
| ||
|---|---|---|---|
| + | − | ||
| 1384 (49.4) | 1419 (50.6) | ||
| Sex | |||
| Male | 748 (54.0) | 757 (53.3) | ns* |
| Female | 636 (46.0) | 662 (46.7) | |
| Age (years) | 67 ± 11 | 62 ± 12 | <0.0001† |
| Duration of diabetes (years) | 12.2 ± 8.5 | 8.8 ± 7.4 | <0.0001† |
| BMI (kg/m2) | 24.0 ± 3.7 | 24.2 ± 3.9 | ns† |
| ≥23 | 789 (57.0) | 836 (58.9) | ns* |
| ≤23 | 579 (41.8) | 578 (40.7) | |
| HbA1c (NGSP) | 7.9 ± 1.5 | 7.6 ± 1.4 | <0.0001† |
| Treatment of diabetes | |||
| Diet and exercise therapy | 167 (12.1) | 344 (24.2) | <0.0001* |
| Oral hypoglycemic agent | 957 (69.1) | 944 (66.5) | |
| Insulin | 264 (19.1) | 131 (9.2) | |
| Medication for neuropathy | |||
| + | 371 (26.8) | 99 (7.0) | <0.0001* |
| − | 1013 (73.2) | 1320 (93.0) | |
| Epalrestat | 206 (14.9) | 37 (2.6) | <0.0001* |
| Mecobalamin | 170 (12.3) | 49 (3.5) | <.0001* |
| Mexiletine hydrochloride | 44 (3.2) | 4 (0.3) | <0.0001* |
| Goshajinki‐gan | 15 (1.1) | 3 (0.2) | <0.005* |
| NSAIDS | 7 (0.5) | 9 (0.6) | ns* |
| Others | 34 (2.5) | 23 (1.6) | ns* |
| Light touch sensation of the great toe | |||
| Normal | 702 (50.7) | 1198 (84.4) | <0.0001† |
| Diminished | 408 (29.5) | 158 (11.1) | |
| Loss | 274 (19.8) | 63 (4.4) | |
Data are mean ± SD, or numbers of patients and percentage in parentheses. ns, not significant.
*Chi‐square test.
†Mann–Whitney U test.
Prevalence of diabetic neuropathy by age, diabetes duration and HbA1C
| Age (years) | <40 | 40–49 | 50–59 | 60–69 | ≥70 |
|
| 71 | 198 | 623 | 924 | 987 |
| Prevalence of diabetic neuropathy | 18 (25.4) | 68 (34.3) | 255 (40.9) | 468 (50.6) | 575 (58.3) |
| Duration of diabetes (years) | <5 | 5–9 | 10–14 | 15–19 | ≥20 |
|
| 780 | 638 | 623 | 298 | 310 |
| Prevalence of diabetic neuropathy | 282 (36.2) | 285 (44.7) | 332 (53.3) | 175 (58.7) | 310 (66.8) |
| HbA1C (%, NGSP) | <6.0 | 6.0–6.9 | 7.0–7.9 | 8.0–8.9 | ≥9.0 |
|
| 355 | 1000 | 742 | 352 | 354 |
| Prevalence of diabetic neuropathy | 146 (41.1) | 454 (45.4) | 364 (49.1) | 212 (60.2) | 208 (58.8) |